Avastin and Lucentis are equally effective in treating age-related macular degeneration (AMD) study suggests

Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD.

Read the whole article on Science Daily

More from Science Daily